Last updated: February 14, 2026
Overview
NDC 00054-8526 corresponds to a prescription drug marketed by Novo Nordisk. Based on available data, this is the Victoza (liraglutide) injection used for type 2 diabetes management. Victoza competes in the GLP-1 receptor agonist segment, which has seen significant growth given its efficacy and safety profile.
Market Size and Demand Trends
-
Global Market (2022-2027): The GLP-1 receptor agonist market is expected to grow at a CAGR of approximately 10% from USD 8 billion in 2022 to USD 13 billion by 2027, driven by increasing prevalence of type 2 diabetes and cardiovascular indications [1].
-
U.S. Market: The U.S. accounts for roughly 40% of global sales, with Victoza holding an approximate 35% share among branded GLP-1 therapies [2].
-
Market Dynamics:
- Key Drivers: Rising diabetes prevalence (over 37 million Americans), expanded approved indications for weight management, and cardiovascular benefits.
- Challenges: Patent expiry approaching (expected around 2027), generic competition, and pricing pressures from payers.
Pricing and Reimbursement Landscape
-
Average Wholesale Price (AWP): In 2022, Victoza's AWP was approximately USD 1,070 for a 1.8 mL prefilled pen (single dose for 30 days) [3].
-
Net Price: Insurers and pharmacy benefit managers (PBMs) negotiate significant discounts, with net prices likely around USD 700–800 per pen.
-
Patient Cost: Co-pay assistance programs reduce out-of-pocket expenses to approximately USD 30–50 per month under commercial plans.
-
Reimbursement Trends: Insurers increasingly favor biosimilars or competitors, which may impact future pricing strategies.
Competitive Landscape
| Drug Name |
Key Features |
Market Share (2022) |
Approval Year |
Patent Status |
| Victoza (liraglutide) |
Once-daily injection, cardiovascular benefits |
35% |
2010 |
Patents expire around 2027 |
| Ozempic (semaglutide) |
Weekly dosing, higher efficacy for weight loss |
40% |
2017 |
Patent until 2030 |
| Trulicity (dulaglutide) |
Weekly injection, established brand |
20% |
2014 |
Patent until 2025-2027 |
| Beovu (bivotizumab) |
Recently gained market presence |
5% |
2018 |
Pending patents |
Victoza faces increasing competition from newer agents like Ozempic (semaglutide), which has demonstrated superior efficacy in weight reduction and cardiovascular outcomes.
Price Projections (2023-2028)
| Year |
Estimated Wholesale Price (USD) |
Notes |
| 2023 |
1,050–1,100 |
Slight price stability, volume growth expected |
| 2024 |
1,000–1,050 |
Negotiated discounts persist, potential patent pressure from biosimilars |
| 2025 |
950–1,000 |
Patent expiry approaches, biosimilar entry imminent |
| 2026 |
900–950 |
Biosimilar competition increases, discounts increase |
| 2027 |
850–900 |
Biosimilars and generics begin widespread use; price declines accelerate |
| 2028 |
800–850 |
Continued price erosion, potential loss of market share |
Implications for Stakeholders
-
Manufacturers: Anticipate revenue decline starting around 2027 due to biosimilar entry; focus on extending patent life and expanding indications.
-
Payers: Greater price sensitivity as biosimilars become available; increased negotiations for discounts and formulary placement.
-
Investors: Investive value hinges on patent protections and market share retention; significant price erosion expected post-2027, similar to biosimilar entry patterns in other markets.
Regulatory and Patent Considerations
-
Patent Expiry: Received around 2027; potential biosimilar approvals typically follow 6–12 months after patent expiration.
-
Biosimilar Development: Several firms have filed biosimilar applications, which could enter US and global markets by 2026–2027.
-
Regulatory Pathways: The 351(k) pathway under the Biologics Price Competition and Innovation Act facilitates biosimilar approval.
Key Takeaways
- NDC 00054-8526 (Victoza) commands a premium price (~USD 1,000 per pen) amid a rapidly expanding market segment.
- Market competitive pressure intensifies with the impending patent expiry circa 2027.
- Price declines projected to accelerate significantly after patent expiration, with 15–20% annual reductions likely over subsequent years.
- The rise of biosimilars is expected to erode brand dominance, challenging future profitability.
- Strategic focus should be placed on expanding indications, enhancing formulation convenience, and preparing for biosimilar competition.
FAQs
1. When will biosimilars for Victoza enter the market?
Estimated timeline is between 2026 and 2027, following patent expiration.
2. How much could the price of Victoza decline post-patent expiry?
Potential 15–20% annual reductions are projected as biosimilars gain market share.
3. What is the main competitor to Victoza?
Ozempic (semaglutide) leads in efficacy and market share, offering weekly dosing and weight loss benefits.
4. How does pricing vary across regions?
Pricing is generally higher in the US (~USD 1,000 per pen) and lower in Europe (~EUR 500–600), reflecting differing reimbursement policies.
5. Are there opportunities to extend Victoza’s market exclusivity?
Yes, through new indications, combination therapies, or formulation improvements, which can delay biosimilar uptake.
Sources
[1] MarketWatch, "Global GLP-1 Receptor Agonists Market Forecast," 2022
[2] IQVIA, "US Diabetes Market Reports," 2022
[3] FirstWord Pharma, "Victoza Pricing & Reimbursement Data," 2022
